Clinical Trials & Medical Discoveries

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress

by

Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is reported: CD43s, a sialylated-glyco epitope, and U5snRNP200, an ectopically expressed antigen highly specific for AML blast Lead program KBA1412 is advancing in … Read more

Publication of data from WIL-31 study marks a milestone in improving long-term care for patients with severe von Willebrand disease (VWD)

by

WIL-31 is the largest prospective prophylaxis study in VWD WIL-31 is the only study in VWD with a prospective on-demand run-in study as an intra-individual comparator wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD vs prior on-demand treatment LACHEN, Switzerland, Jan. 22, 2024 /PRNewswire/ — Octapharma … Read more

Más precisión en el tratamiento de tumores gracias a la tecnología superconductora de ASG Superconductors

by

GINEBRA, Italia y DRESDEN, Alemania, 11 de enero de 2024 /PRNewswire/ — La tecnología superconductora MgB2 de ASG Superconductors (ASG), la cual ya se utiliza en aplicaciones energéticas y médicas, siendo el único sistema de resonancias magnéticas (IRM) MROpenEVO verdaderamente abierto del mundo, está en el corazón de la innovación mundial presentada hoy en Dresde … Read more

Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches

by

 Findings suggest “less is more” and “tried and true” may benefit select patients SAN DIEGO, Dec. 10, 2023 /PRNewswire/ — Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, … Read more

University of Maryland and BioGenCell Announce the Launch of BioGenCell Fifth Chronic Limb-Threatening Ischemia Clinical Trial Site in the United States

by

BioGenCell has announced the inauguration of the fifth Phase II cell-therapy-based clinical trial site for Chronic Limb-Threatening Ischemia (CLTI) in the United States at the University of Maryland, Baltimore. This initiative is committed to dramatically reducing the incidence of amputations in patients afflicted with severe CLTI. BALTIMORE, Dec. 7, 2023 /PRNewswire/ — BioGenCell, a pioneer … Read more

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

by

Updated data from the Phase I trial of RVU120 in relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) demonstrate clinically relevant benefit in 50% of evaluable patients Preclinical data support RVU120 as a novel agent for the treatment of patients with lower-risk MDS (LR-MDS) and show cytotoxic and differentiating effects on leukemic stem cells … Read more

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations

by

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system  Phase 1 results show a manageable safety profile with limited systemic toxicity, and early complete responses in patients with high-risk and intermediate-risk NMIBC MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & … Read more

New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

by

Data show the potential impact of RYBREVANT® and chemotherapy combination as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations Late-breaking data presented in a Presidential Symposium at 2023 ESMO Congress and simultaneously published in The New England Journal of Medicine MADRID, Oct. 21, 2023 /PRNewswire/ — … Read more

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1

by

New AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting previously reported positive data showing improvements in myotonia, muscle strength and mobility   New long-term safety data of AOC 1001 continue to demonstrate favorable safety and tolerability with over 200 infusions totaling 46.2 patient-years of … Read more

National University Health System Launches World’s First Public Hospital’s Healthy Longevity Clinic at Alexandra Hospital

by

SINGAPORE, Sept. 2, 2023 /PRNewswire/ — The National University Health System (NUHS), NUS Yong Loo Lin School of Medicine and Alexandra Hospital (AH) have achieved a milestone by unveiling the world’s inaugural Healthy Longevity Clinic by public healthcare. Located at Singapore’s Alexandra Hospital, the clinic aims to delay biological ageing, thereby optimising functionality and resilience and … Read more